💊 Thuốc A-Z 🧬 Đích tác dụng 🛠 Công cụ 📚 Hướng dẫn
Tất cả thuốc Phân loại thuốc Lĩnh vực điều trị Tác dụng phụ
Hướng dẫn Từ điển thuật ngữ Dòng thời gian
So sánh Hành trình của thuốc Các họ thuốc
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Siponimod

CHEMBL2336071 Phase 4 Đã phê duyệt Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
516.6 g/mol
LogP
4.8
Phase
4

Siponimod is a selective sphingosine-1-phosphate receptor modulator (S1P1 and S1P5) used for the treatment of active secondary progressive multiple sclerosis (SPMS). By binding to S1P1 receptors on lymphocytes, it causes their sequestration in lymph nodes, reducing pathogenic lymphocyte migration into the CNS and associated neuroinflammation and demyelination. Its selectivity for S1P5, expressed on oligodendrocytes and NK cells, may provide additional neuroprotective effects relevant to SPMS progression.

Khối lượng phân tử

516,6000 g/mol

LogP

4,80

TPSA

62,10 Ų

Lipinski RO5

Đạt

Lĩnh vực điều trị

Multiple Sclerosis Stroke

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cấu trúc 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CCc1cc(/C(C)=N/OCc2ccc(C3CCCCC3)c(C(F)(F)F)c2)ccc1CN1CC(C(=O)O)C1

                

                

                
                

                    
InChI

                    
InChI=1S/C29H35F3N2O3/c1-3-21-14-23(10-11-24(21)15-34-16-25(17-34)28(35)36)19(2)33-37-18-20-9-12-26(22-7-5-4-6-8-22)27(13-20)29(30,31)32/h9-14,22,25H,3-8,15-18H2,1-2H3,(H,35,36)/b33-19+

                

                

                

                    
                    

                        
Molecular Formula

                        
C29H35F3N2O3

                    

                    
                    

                        
HBD / HBA

                        
1 / 8

                    

                    
                    

                        
Liên kết có thể quay

                        
9

                    

                    
                    
                    

                        
Nguyên tử nặng

                        
37

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Câu hỏi thường gặp

                

                    
                    

                        
                        

                            
Siponimod is a selective sphingosine-1-phosphate receptor modulator (S1P1 and S1P5) used for the treatment of active secondary progressive multiple sclerosis (SPMS). By binding to S1P1 receptors on lymphocytes, it causes their sequestration in lymph nodes, reducing pathogenic lymphocyte migration into the CNS and associated neuroinflammation and demyelination. Its selectivity for S1P5, expressed on oligodendrocytes and NK cells, may provide additional neuroprotective effects relevant to SPMS progression.

                        

                    

                    

                    

                    

                    

                    

                        
                        

                            
Yes, Siponimod is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL2336071.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 44599207.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Tuyên bố miễn trách y tế

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.